KeyBanc reiterates Elanco Animal Health stock rating on strong parasiticide trends

KeyBanc reiterated an Overweight rating and $30 price target on Elanco after a survey of 50 U.S. veterinary clinics showed 64% were prescribing more broad-spectrum parasiticides year over year, with Quattro and Zenrelia adoption remaining strong. The survey also supports Zoetis's Simparica Trio gross-to-net strategy, but Zoetis continues to face softer companion-animal demand, competitive pressure and weak clinic traffic; its shares are down 43% year to date near a 52-week low. Zoetis's Q2 2026 adjusted EPS of $1.87 narrowly beat the $1.86 consensus, while $2.50B revenue missed the $2.51B estimate and management lowered full-year guidance.

Analysis

The actionable read-through is a relative-share shift rather than a broad animal-health demand recovery. ELAN’s newer companion-animal launches can compound through formulary adoption and repeat prescriptions, while ZTS faces a more difficult mix: promotional spending may defend prescription volume but dilutes realized pricing and leaves less room to offset weaker clinic traffic. A 50-clinic channel check is directionally useful but not sufficient to underwrite a standalone earnings revision; prescription data, distributor inventory and gross-to-net disclosures matter more.

Over the next 1-3 months, ELAN has a cleaner path to positive estimate revisions if launch velocity persists into the next reporting cycle, whereas ZTS likely needs evidence that net-price investment is stabilizing share without impairing margins. The key second-order risk for ZTS is that economic competition in parasiticides trains clinics and pet owners to trade down, making eventual price restoration difficult even if volume recovers. For ELAN, efficacy-driven adoption is more durable than discount-driven switching, but payer/formulary access and manufacturing availability remain the gating variables.

Consensus may be too quick to treat ZTS’s valuation compression as a simple mean-reversion opportunity. A lower multiple is justified if its historical premium growth algorithm has shifted to lower volume growth, higher rebates and incrementally greater product-cycle risk; the relevant catalyst is not an inexpensive screen valuation but a return to organic growth and gross-margin durability. Conversely, the market may be underpricing ELAN’s operating leverage if new-product mix can replace slower legacy categories without materially higher selling expense over the next 6-18 months.

Key Decisions for Investors

• Initiate a 3-6 month long ELAN / short ZTS dollar-neutral pair after confirming the next monthly prescription or distributor-data trend remains favorable for ELAN. Target 15-20% relative return; exit if ELAN launch-product growth decelerates materially or ZTS demonstrates sequential net-price and market-share stabilization.
• Use ZTS earnings as a catalyst watch rather than buy the drawdown immediately: remain underweight until management shows that gross-to-net investment is not causing a meaningful gross-margin or full-year EPS reset. A credible raised organic-growth outlook and stable margin guide would falsify the bearish leg.
• For ELAN, add only on evidence of sustained prescription conversion rather than clinic intent surveys—specifically, management confirmation of continued share gains and no deterioration in launch-related commercial expense. If those data are absent, keep position size modest because the thesis depends on execution rather than category growth.
• Avoid SF as a direct expression of this setup; its inclusion is not supported by a clear revenue or valuation transmission mechanism from companion-animal prescription trends.